| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Samantha Alvarez-Herrera, Mauricio Rosel Vales, Gilberto Pérez-Sánchez, Enrique Becerril-Villanueva, Yvonne Flores-Medina, José Luis Maldonado-García, Ricardo Saracco-Alvarez, Raúl Escamilla, Lenin Pavó. Risperidone Decreases Expression of Serotonin Receptor-2A (5-HT2A) and Serotonin Transporter (SERT) but Not Dopamine Receptors and Dopamine Transporter (DAT) in PBMCs from Patients with Schizophrenia. Pharmaceuticals (Basel, Switzerland). vol 17. issue 2. 2024-02-24. PMID:38399382. |
however, the use of polytherapy to treat schizophrenia makes it challenging to determine the specific effects of risperidone on peripheral blood mononuclear cells (pbmcs). |
2024-02-24 |
2024-02-26 |
Not clear |
| Mingwei Gao, Fuqi Wang, Chuanyao Sun, Shuzhuo Zhang, Ruibin S. Effects of olanzapine on hippocampal CA3 and the prefrontal cortex local field potentials. European journal of pharmacology. 2024-02-07. PMID:38325793. |
olanzapine is an antipsychotic drug applied in psychiatry to treat psychoses, especially schizophrenia and schizoaffective disorders with similar or better improvement than haloperidol and risperidone in the treatment of depressive and negative symptoms. |
2024-02-07 |
2024-02-10 |
Not clear |
| Xiaobing Lu, Qianqian Sun, Ling Wu, Meisi Liao, Jing Yao, Meihong Xi. The neutrophil-lymphocyte ratio in first-episode medication-naïve patients with schizophrenia: A 12-week longitudinal follow-up study. Progress in neuro-psychopharmacology & biological psychiatry. 2024-02-04. PMID:38311095. |
one hundred and ninety-five medication-naïve first-episode schizophrenia (mnfes) patients were recruited and received treatment with risperidone for 12 weeks in the present study. |
2024-02-04 |
2024-02-07 |
Not clear |
| Wenyan Wang, Xiaofeng Wang, Ying Dong, David P Walling, Pinglan Liu, Wanhui Liu, Yanan Shi, Kaoxiang Su. Population Pharmacokinetic Analysis to Support and Facilitate Switching from Risperidone Formulations to Rykindo in Patients with Schizophrenia. Neurology and therapy. 2024-01-20. PMID:38244179. |
population pharmacokinetic analysis to support and facilitate switching from risperidone formulations to rykindo in patients with schizophrenia. |
2024-01-20 |
2024-01-23 |
Not clear |
| Wenyan Wang, Xiaofeng Wang, Ying Dong, David P Walling, Pinglan Liu, Wanhui Liu, Yanan Shi, Kaoxiang Su. Population Pharmacokinetic Analysis to Support and Facilitate Switching from Risperidone Formulations to Rykindo in Patients with Schizophrenia. Neurology and therapy. 2024-01-20. PMID:38244179. |
rykindo® (rykindo) is a novel, long-acting injectable risperidone formulation administered biweekly (q2w) through intramuscular gluteal injection for the treatment of schizophrenia in adult patients. |
2024-01-20 |
2024-01-23 |
Not clear |
| Xiaoyi Wang, Jing Huang, Jianjun Lu, Xuemei Li, Hui Tang, Ping Sha. Risperidone plasma level, and its correlation with CYP2D6 gene polymorphism, clinical response and side effects in chronic schizophrenia patients. BMC psychiatry. vol 24. issue 1. 2024-01-10. PMID:38200532. |
risperidone plasma level, and its correlation with cyp2d6 gene polymorphism, clinical response and side effects in chronic schizophrenia patients. |
2024-01-10 |
2024-01-13 |
Not clear |
| Xiaoyi Wang, Jing Huang, Jianjun Lu, Xuemei Li, Hui Tang, Ping Sha. Risperidone plasma level, and its correlation with CYP2D6 gene polymorphism, clinical response and side effects in chronic schizophrenia patients. BMC psychiatry. vol 24. issue 1. 2024-01-10. PMID:38200532. |
to explore the influence of cyp2d6 genetic polymorphism on risperidone metabolism, thereby affecting risperidone's effects and safeties in patients with chronic schizophrenia. |
2024-01-10 |
2024-01-13 |
Not clear |
| Xiaoe Lang, Dongmei Wang, Dachun Chen, Meihong Xiu, Huixia Zhou, Li Wang, Bo Cao, Xiangyang Zhan. Association Between Hippocampal Subfields and Clinical Symptoms of First-Episode and Drug Naive Schizophrenia Patients During 12 Weeks of Risperidone Treatment. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. vol 19. issue 1. 2024-01-04. PMID:38176805. |
association between hippocampal subfields and clinical symptoms of first-episode and drug naive schizophrenia patients during 12 weeks of risperidone treatment. |
2024-01-04 |
2024-01-07 |
human |
| John M Kane, Eran Harary, Roy Eshet, Orna Tohami, Mark Weiser, Stefan Leucht, Avia Merenlender-Wagner, Nir Sharon, Glen L Davis, Mark Suett, Kelli R Franzenburg, Christoph U Correl. Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria. The lancet. Psychiatry. 2023-11-04. PMID:37924833. |
efficacy and safety of tv-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the usa and bulgaria. |
2023-11-04 |
2023-11-08 |
Not clear |
| John M Kane, Eran Harary, Roy Eshet, Orna Tohami, Mark Weiser, Stefan Leucht, Avia Merenlender-Wagner, Nir Sharon, Glen L Davis, Mark Suett, Kelli R Franzenburg, Christoph U Correl. Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria. The lancet. Psychiatry. 2023-11-04. PMID:37924833. |
the aim of the phase 3 risperidone subcutaneous extended-release (rise) study was to evaluate the efficacy of tv‑46000 in schizophrenia. |
2023-11-04 |
2023-11-08 |
Not clear |
| Xiaoli Zhu, Chuan-Lan Wang, Jian-Feng Yu, Jianjun Weng, Bing Han, Yanqing Liu, Xiaowei Tang, Bo Pa. Identification of immune-related biomarkers in peripheral blood of schizophrenia using bioinformatic methods and machine learning algorithms. Frontiers in cellular neuroscience. vol 17. 2023-10-16. PMID:37841288. |
a schizophrenia rat model was established to validate clic3 expression and found that clic3 levels were reduced in the model rat plasma and brains in a brain-regional dependent manner, but can be reversed by an antipsychotic drug risperidone. |
2023-10-16 |
2023-11-08 |
rat |
| Hirla Costa Silva Fukushima, Ricardo Lacava Bailone, Ricardo Carneiro Borr. Assessment of Risperidone Toxicity in Zebrafish ( Comparative medicine. vol 73. issue 4. 2023-10-11. PMID:37536933. |
assessment of risperidone toxicity in zebrafish ( risperidone is an antipsychotic medication used in the treatment of conditions like autism and schizophrenia. |
2023-10-11 |
2023-10-15 |
zebrafish |
| Shu-Wen Deng, Qian Xu, Wen-Long Jiang, Bo Hong, Bo-Hui Li, Da-Wei Sun, Hai-Bo Yan. Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials. BMC psychiatry. vol 23. issue 1. 2023-10-11. PMID:37821875. |
efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials. |
2023-10-11 |
2023-10-15 |
Not clear |
| Shu-Wen Deng, Qian Xu, Wen-Long Jiang, Bo Hong, Bo-Hui Li, Da-Wei Sun, Hai-Bo Yan. Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials. BMC psychiatry. vol 23. issue 1. 2023-10-11. PMID:37821875. |
we conducted a systematic review and meta-analysis to evaluate the efficacy and safety of blonanserin and risperidone for the treatment of schizophrenia and to provide reliable pharmacotherapeutic evidence for in the clinical treatment of schizophrenia. |
2023-10-11 |
2023-10-15 |
Not clear |
| Ahmad Shamabadi, Setareh Fattollahzadeh-Noor, Bita Fallahpour, Fatemeh A Basti, Mohammad-Reza Khodaei Ardakani, Shahin Akhondzade. L-Theanine adjunct to risperidone in the treatment of chronic schizophrenia inpatients: a randomized, double-blind, placebo-controlled clinical trial. Psychopharmacology. 2023-09-11. PMID:37697164. |
l-theanine adjunct to risperidone in the treatment of chronic schizophrenia inpatients: a randomized, double-blind, placebo-controlled clinical trial. |
2023-09-11 |
2023-10-07 |
Not clear |
| Pedro Sánchez, Cecilio Álamo, Marcos Almendros, Max Schlueter, Anastasios Tasoulas, Javier Martíne. Extrapyramidal adverse events and anticholinergics use after the long-term treatment of patients with schizophrenia with the new long-acting antipsychotic Risperidone ISM Annals of general psychiatry. vol 22. issue 1. 2023-09-02. PMID:37660132. |
extrapyramidal adverse events and anticholinergics use after the long-term treatment of patients with schizophrenia with the new long-acting antipsychotic risperidone ism risperidone ism |
2023-09-02 |
2023-09-07 |
Not clear |
| Sarah Tedesco, Raquel Gonzalez, Philipa Owusu-Antwi, Raymond E Robinson, Christopher Janus. A Case of Undiagnosed Schizophrenia With Catatonia in a Hispanic Adolescent: The Significance of Social Determinants in the Diagnosis and the Efficacy of Risperidone and Lorazepam in Treatment. Cureus. vol 15. issue 7. 2023-08-29. PMID:37641761. |
a case of undiagnosed schizophrenia with catatonia in a hispanic adolescent: the significance of social determinants in the diagnosis and the efficacy of risperidone and lorazepam in treatment. |
2023-08-29 |
2023-09-07 |
Not clear |
| Siddarthkumar Chawath, Santosh Ramdurg, Sharan Badiger, Shivakumar P Chaukimat. Risperidone-induced anaemia. The National medical journal of India. vol 36. issue 1. 2023-08-24. PMID:37615136. |
risperidone is an atypical antipsychotic drug, which is used in schizophrenia and also to treat excitation and aggression in patients with delirium. |
2023-08-24 |
2023-09-07 |
Not clear |
| Rui Li, Rui Fu, Zhi-Quan Cui, Lin Guo, Yi-Huan Chen, Jie Bai, Jia-Bin Yang, Qing-Rong Tan, Zheng-Wu Pen. Effects of low-Frequency rTMS combined with risperidone on the gut microbiome in Hospitalized Patients with Chronic Schizophrenia. Brain research. 2023-08-20. PMID:37598899. |
effects of low-frequency rtms combined with risperidone on the gut microbiome in hospitalized patients with chronic schizophrenia. |
2023-08-20 |
2023-09-07 |
Not clear |
| Qiuying Chen, Jie Min, Haibo Yin, Wenying Xia, Yimin Shen, Ming Sh. Relationship between clinical efficacy and plasma concentration-dose ratio of risperidone in patients with schizophrenia. International clinical psychopharmacology. 2023-08-08. PMID:37551602. |
relationship between clinical efficacy and plasma concentration-dose ratio of risperidone in patients with schizophrenia. |
2023-08-08 |
2023-08-14 |
Not clear |